New Products

FDA Approves New Asthma Indication for Trelegy Ellipta

September 10, 2020

Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta; GlaxoSmithKline) is indicated for the treatment of asthma in patients aged 18 years and older.

FDA OKs Tramadol Hydrochloride Oral Liquid for Pain Management

September 09, 2020

Tramadol hydrochloride (Qdolo; Athena Bioscience) oral solution is indicated for use when pain is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

FDA OKs Azacitidine Tablets for Acute Myeloid Leukemia

September 03, 2020

Oral azacitidine (Onureg; Celgene) is approved for patients in first remission with acute myeloid leukeimia.

Coronavirus News Roundup: FDA Issues EUA for Rapid Antigen Test, ASHP Releases COVID-19 Vaccine Guidelines

August 28, 2020

Here's the coronavirus-related news from this week that you should know.

FDA Issues Emergency Use Authorization to New 15-Minute COVID-19 Antigen Test

August 27, 2020

Abbott’s BinaxNOW COVID-19 Ag Card rapid test produces results in 15 minutes.

Amisulpride Injection Now Available in the US for Postoperative Nausea and Vomiting

August 25, 2020

Amisuplride injection (Barhemsys; Acacia) is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed prior prophylaxis with an agent of a different class.

Mylan Launches Generic Version of Multiple Sclerosis Treatment

August 20, 2020

Mylan has launched the first FDA-approved generic version of Biogen’s dimethyl fumarate (Tecfidera) for relapsing forms of multiple sclerosis.

FDA OKs Risdiplam for Treatment of Spinal Muscular Atrophy

August 07, 2020

Risdiplam (Evrysdi; Genentech) is the only SMA therapy that can be administered at home.

Stay in Sync with Innovations in Medication Decision Support

August 06, 2020

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA OKs New Indication for Esketamine Nasal Spray

August 05, 2020

Esketamine (Spravato; Janssen) CIII nasal spray is the first FDA-approved antidepressant medication that improves depressive symptoms with the first dose in adults with major depressive disorder.